(Q46118058)

19 December 2017

title

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer (English)

1 reference

19 December 2017

author name string

Fausto Petrelli

1

1 reference

19 December 2017

Karen Borgonovo

2

1 reference

19 December 2017

Veronica Lonati

3

1 reference

19 December 2017

Stefano Elia

4

1 reference

19 December 2017

Sandro Barni

5

1 reference

19 December 2017

publication date

30 November 2012

1 reference

19 December 2017

published in

Targeted oncology

1 reference

19 December 2017

volume

8

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

291-294

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1007/s11523-012-0240-y

exact match

0 references

cites work

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

The current and future management of malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Malignant ascites: systematic review and guideline for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-012-0240-Y

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer

21 January 2018

1 reference

12 December 2020

Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer

1 reference

12 December 2020

Current and future options in the treatment of malignant ascites in ovarian cancer.

1 reference

12 December 2020

The pathogenesis of malignant ascites.

1 reference

12 December 2020

10.1007/S11523-012-0240-Y

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017